Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

NCT03382405 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: mRNA-1647/mRNA-1443-P101
• Study Type: interventional
• Target: 181
• Locations: 1 country
• Sites: 4

Brief Summary

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults

Conditions

Cytomegalovirus Infection

Keywords

cytomegalovirus vaccine; mRNA-1647; mRNA-1443; Moderna

Outcome Measures

Primary Outcomes (4)

• Frequency of solicited AEs (local and systemic reactogenicity events)

  7 days following each dose administration

• Frequency of unsolicited adverse events

  29 days following each dose administration

• Frequency of medically-attended AEs, adverse events of special interest (AESI), and serious adverse events (SAE)

  one year following the last dose administration

• Frequency of clinical laboratory adverse events

  1 month following the last dose administration

Secondary Outcomes (4)

• Titers of anti-CMV neutralizing antibodies against epithelial cell infection measured by neutralization assay in comparison with baseline sample

  6 months following the last dose administration

• Titers of anti-CMV neutralizing antibodies against fibroblast cell infection measured by neutralization assay in comparison with baseline sample

  6 months following the last dose administration

• Titers of vaccine antigen-specific IgG antibodies as measured by ELISA assay in comparison with baseline sample

  6 months following the last dose administration

• Frequencies of vaccine antigen-specific CD4 and CD8 T cells secreting interferon gamma as determined by ELISPOT

  6 months following the last dose administration

Study Arms (3)

mRNA-1647

EXPERIMENTAL

Biological: mRNA-1647

mRNA-1443

EXPERIMENTAL

Biological: mRNA-1443

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

mRNA-1647 BIOLOGICAL

Escalating dose levels

mRNA-1647

mRNA-1443 BIOLOGICAL

Escalating dose levels

mRNA-1443

Placebo OTHER

Saline

Placebo

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Agrees to comply with the study procedures and provides written informed consent
• to 49 years of age
• Body mass index between 18 and 35 kg/m2
• In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination
• Negative urine pregnancy test at the Screening visit and the day of each vaccination for females of childbearing potential
• Female subjects must either be of non-childbearing potential or use acceptable methods of contraception from at least 30 days prior to enrollment and through 3 months following last vaccination
• Male subjects must agree to practice adequate contraception for 30 days prior to the first vaccination and through 3 months following the last vaccination
• Willing to comply with the requirements of the protocol (eg, complete Diary Cards, return for follow-up visits, be available for safety phone calls)

You may not qualify if:

• Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
• A history of malignancy in the last 10 years
• If female and of childbearing potential, is pregnant or lactating, has not adhered to an adequate contraception method from at least 30 days before study entry, or does not plan to do so for at least 3 months after the last vaccination.
• Abnormal screening safety laboratory test results including liver enzyme tests
• Administration of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine or has plans for administration during the study period
• Prior administration of investigational agent using lipid nanoparticle formulations
• A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
• A positive test result for drugs of abuse
• Chronic administration of potentially hepatotoxic drugs or have other medical conditions that affect the liver (eg, alcohol abuse)
• A history of idiopathic urticaria
• Plans for administration or has been administered a vaccine within the period from 30 days before through 30 days after each study vaccination, with the exception of any licensed influenza vaccine administered ≥15 days before or after any study vaccination
• Any chronic administration of an immunosuppressant or other immune modifying drug
• Prior administration of immunoglobulins and/or any blood products within the 3 months before the first study vaccine or has plans for administration during the study period
• Any known or suspected immune-mediated disease or immunosuppressive condition as determined by medical history and/or physical examination
• A history of hypersensitivity or serious reactions to previous vaccinations

Sponsors & Collaborators

• ModernaTX, Inc.: lead

Study Sites (4)

Research Centers of America

Hollywood, Florida, 33024, United States

Location

Advanced Clinical Research

Meridian, Idaho, 83642, United States

Location

Optimal Research

Peoria, Illinois, 61614, United States

Location

Johnson County Clinical Trials

Lenexa, Kansas, 66219, United States

Location

Related Publications (3)

• Wu K, Hou YJ, Makrinos D, Liu R, Zhu A, Koch M, Yu W-H, Paila YD, Chandramouli S, Panther L, Henry C, DiPiazza A, Carfi A. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults. J Virol. 2024 Apr 16;98(4):e0160323. doi: 10.1128/jvi.01603-23. Epub 2024 Mar 25.

  PMID: 38526054 DERIVED

• Fierro C, Brune D, Shaw M, Schwartz H, Knightly C, Lin J, Carfi A, Natenshon A, Kalidindi S, Reuter C, Miller J, Panther L. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial. J Infect Dis. 2024 Sep 23;230(3):e668-e678. doi: 10.1093/infdis/jiae114.

  PMID: 38478705 DERIVED

• Hu X, Karthigeyan KP, Herbek S, Valencia SM, Jenks JA, Webster H, Miller IG, Connors M, Pollara J, Andy C, Gerber LM, Walter EB, Edwards KM, Bernstein DI, Hou J, Koch M, Panther L, Carfi A, Wu K, Permar SR. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine. J Infect Dis. 2024 Aug 16;230(2):455-466. doi: 10.1093/infdis/jiad593.

  PMID: 38324766 DERIVED

MeSH Terms

Conditions

Cytomegalovirus Infections

Interventions

mRNA-1647 cytomegalovirus vaccine

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2017
• First Posted: December 22, 2017
• Study Start: November 13, 2017
• Primary Completion: October 28, 2020
• Study Completion: October 28, 2020
• Last Updated: January 15, 2021

Record last verified: 2021-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (4)